Indiana Biosciences Research Institute Keeps MBX Biosciences Growing in Indiana

INDIANAPOLIS (October 29, 2025) – The Indiana Biosciences Research Institute (IBRI) continues to strengthen Indiana’s position as a national leader in life sciences innovation by supporting the growth and success of MBX Biosciences, Inc. (MBX), a clinical-stage biopharmaceutical company co-founded by Kent Hawryluk and Richard DiMarchi, PhD.

MBX is focused on the discovery and development of novel precision peptide therapies based on its proprietary Precision Endocrine Peptide™ (PEP™) platform for the treatment of endocrine and metabolic disorders. MBX is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities.

“IBRI was established to advance research and innovation that drive economic and health impact,” said Ari Landon, PhD, MBA, IBRI Chief Scientific Business Officer, “The growth of MBX Biosciences exemplifies how Indiana’s collaborative ecosystem of academic, industry, and philanthropic partners fuels breakthrough science and keeps world-class companies rooted in our state.”

As MBX Biosciences advances its clinical programs and expands operations, its ongoing presence in Indiana underscores the state’s growing reputation as a global hub for biotechnology and translational research.”